when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

376 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT1020 Endpoints770 BioPharma Dive293 BioSpace210 Fierce Biotech198 onclive165 raps74 globenewswire health

therapy area

all Oncology5954 Rare Disease1405 Cardiology1088 Hematology1011 Immunology992 Pulmonology892 Vaccines

Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma
Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.
onclive · 3mo ago↗ source
FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC
An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC
onclive · 3mo ago↗ source
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
onclive · 3mo ago↗ source

page 15 of 16

73

885

Psychiatry & CNS710

Ophthalmology419

Endocrinology & Metabolism377

Infectious Disease346

Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma

Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.

onclive · 3mo ago↗ source

Dr Sznol on Biomarkers of Response in Metastatic Melanoma

Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma.

onclive · 3mo ago↗ source

Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery

The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.

onclive · 3mo ago↗ source

ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

onclive · 3mo ago↗ source

Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management

Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.

onclive · 3mo ago↗ source

Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration

New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.

onclive · 3mo ago↗ source

Disease Assessment and Mutational Testing in Progressive CLL

Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.

onclive · 3mo ago↗ source

Clinical Scenario Presentation and Treatment Approach for Progressive Disease

Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.

onclive · 3mo ago↗ source

Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC

Shubham Pant, MD, MBBS, explains the unique "on-state" binding mechanism of daraxonrasib.

onclive · 3mo ago↗ source

Four-Year Follow-Up Outcomes in dMMR Endometrial Cancer Presented at SGO 2026

SGO 2026 data shows frontline checkpoint inhibitors in dMMR gynecologic cancer drive flat survival curves, hinting at cure and less chemo.

onclive · 3mo ago↗ source

Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCC

Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.

onclive · 3mo ago↗ source

Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer

Deirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.

onclive · 3mo ago↗ source

Dr Pant on Managing Toxicities With Daraxonrasib in PDAC

Shubham Pant, MD, MBBS, discusses the management of dermatologic and GI toxicities associated with the RAS(ON) inhibitor daraxonrasib.

onclive · 3mo ago↗ source

HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistance

Phase 1 data show HS-10504 yields encouraging responses and manageable safety in EGFR C797S–mutant NSCLC post TKI therapy.

onclive · 3mo ago↗ source

Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress

Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress.

onclive · 3mo ago↗ source

The Type of Fat—Not the Amount—Fuels Pancreatic Cancer

Research from Yale Cancer Center showed that the type of fat consumed may matter more than amount in pancreatic cancer.

onclive · 3mo ago↗ source

Iopofosine I 131 Follow-Up Data Show Strong Efficacy in Waldenström Macroglobulinemia

Iopofosine I 131 produced strong responses in Waldenström macroglobulinemia, according to 12-month folllow-up data from CLOVER WaM requested by the FDA.

onclive · 3mo ago↗ source

Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC

Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.

onclive · 3mo ago↗ source

Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis

Andrew Kuykendall, MD, explains considerations for JAK inhibitor sequencing and the use of transplant in myelofibrosis.

onclive · 3mo ago↗ source

New Endometrial Targets Beyond HER2

Interest in endometrial cancer extends well beyond HER2, and the faculty review a growing pipeline of antibody drug conjugates directed at additional targets. Discussion includes why TROPE2 and oth…

onclive · 3mo ago↗ source

Coordinating Care in Multiple Myeloma Across Practice Settings

onclive · 3mo ago↗ source

EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progression

In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase…

onclive · 3mo ago↗ source